Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUPRENORPHINE HYDROCHLORIDE vs BUPRENORPHINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Partial agonist at mu-opioid receptors and antagonist at kappa-opioid receptors, producing analgesia and reducing opioid withdrawal symptoms.
Partial mu-opioid receptor agonist and weak kappa-opioid receptor antagonist; also exhibits high affinity but low intrinsic activity at mu-opioid receptors, producing analgesia and euphoria with a ceiling effect on respiratory depression.
Treatment of opioid dependence (buprenorphine/naloxone combination),Management of moderate to severe pain (buprenorphine transdermal or buccal formulations)
Treatment of opioid dependence (Subutex, Suboxone),Moderate to severe pain (parenteral formulation, e.g., Buprenex),Off-label: Treatment of depression (as adjunctive therapy), chronic pain in opioid-tolerant patients, and neonatal abstinence syndrome (probable).
Sublingual: 8-16 mg once daily. Transdermal: 5-20 mcg/hour applied every 7 days. Injectable: 0.3 mg IM/IV every 6-8 hours as needed.
Sublingual tablet: 2-8 mg every 6-8 hours as needed for pain; for opioid use disorder: 12-16 mg once daily. Transdermal patch: 5-20 mcg/h applied every 7 days. IV/IM: 0.3 mg every 6-8 hours.
Terminal elimination half-life is 20-73 hours (mean ~37 hours); prolonged half-life supports sublingual dosing every 24-48 hours in opioid dependence.
Terminal elimination half-life is 24-60 hours (mean ~37 hours) due to enterohepatic recirculation and slow dissociation from mu-opioid receptors. Clinically, this allows for every-other-day or thrice-weekly dosing in maintenance therapy.
Primarily metabolized by CYP3A4 to norbuprenorphine; also glucuronidated by UGT1A1, UGT2B7.
Primarily hepatic via N-dealkylation to norbuprenorphine via CYP3A4, with minor contribution from CYP2C8; norbuprenorphine is active and further glucuronidated; undergoes extensive first-pass metabolism; mainly excreted in feces (as unchanged drug and metabolites) and to a lesser extent in urine.
Primarily fecal (70%) via biliary excretion; renal excretion accounts for 20-30% as unchanged drug and metabolites (mainly norbuprenorphine glucuronide).
Buprenorphine is primarily eliminated via biliary excretion of its metabolites, with approximately 70% of the dose recovered in feces as unchanged drug and metabolites. Renal elimination accounts for about 10-30%, primarily as metabolites.
96% bound primarily to alpha- and beta-globulins, with negligible binding to albumin.
Approximately 96% bound to alpha- and beta-globulins, with minimal binding to albumin.
2.5 L/kg (range 1.5-5 L/kg); high Vd indicates extensive tissue distribution (e.g., brain, adipose).
Volume of distribution is 2-4 L/kg (mean ~3.2 L/kg). High Vd indicates extensive tissue distribution, including sequestration in brain and adipose tissue.
Sublingual: 30-50% (range 15-55%); buccal: 30-50%; oral: <10% due to extensive first-pass metabolism; intramuscular: 90-100%; intravenous: 100%.
Sublingual: 30-55% (variable due to first-pass metabolism); Oral: ~15% (low due to extensive hepatic metabolism); Transdermal: ~15-20%; Intravenous/Intramuscular: 100%.
No dosage adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, use with caution and consider reducing dose or extending interval. Not dialyzable.
No dosage adjustment required for mild to moderate impairment (GFR >30 m L/min). For severe impairment (GFR <30 m L/min), consider reducing dose and increasing interval; avoid in anuric patients.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce starting dose by 50% (e.g., sublingual 4 mg). Child-Pugh C: Avoid use or reduce dose by 75% (e.g., sublingual 2 mg).
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% and monitor. Child-Pugh C: contraindicated or use with extreme caution with significant dose reduction (e.g., 50-75% reduction).
Not approved for <16 years. For induction in adolescents: Sublingual 2-4 mg initially, titrated based on response. Maximum 24 mg/day.
For pain (≥2 years): sublingual tablet 2-6 mcg/kg every 4-8 hours; IV/IM 2-6 mcg/kg every 4-6 hours. For opioid use disorder (≥16 years): induction 2-4 mg, then titration to 12-16 mg once daily; safety in <16 years not established.
Reduce initial dose by 25-50% due to increased sensitivity. Titrate slowly. Monitor for respiratory depression and CNS effects.
Initiate at lowest dose (e.g., sublingual 2 mg, transdermal 5 mcg/h) and titrate slowly due to increased sensitivity and risk of respiratory depression, falls, and cognitive impairment; monitor renal and hepatic function.
WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; WARNING: RISK OF RESPIRATORY DEPRESSION, ADDICTION, ABUSE, AND MISUSE; WARNING: RISK OF NEONATAL OPIOID WITHDRAWAL SYNDROME
Risk of respiratory depression, particularly in non-opioid-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of serious harm or death with concomitant use of benzodiazepines or CNS depressants; requirement for patient access to emergency medical services and monitoring; risk of addiction, abuse, and misuse; risk of accidental exposure.
Respiratory depression (especially with benzodiazepines or other CNS depressants), neonatal opioid withdrawal syndrome during prolonged use in pregnancy, risk of hepatitis or hepatic injury, adrenal insufficiency, hypotension, QT prolongation, opioid-induced hyperalgesia, risk of withdrawal with partial agonist, misuse potential.
Respiratory depression: ceiling effect exists, but risk increases with non-opioid-tolerant use or coadministration of CNS depressants,Potentiation of respiratory depression by benzodiazepines and alcohol,Neonatal opioid withdrawal syndrome: avoid prolonged use during pregnancy unless necessary,Adrenal insufficiency: risk with prolonged use,Androgen deficiency: may occur with chronic use,Hypotension, especially in hypovolemic patients,Biliary tract spasm: may cause constriction of sphincter of Oddi,Risk of misuse, abuse, and diversion
Hypersensitivity to buprenorphine, severe respiratory depression, acute or severe bronchial asthma, known or suspected gastrointestinal obstruction (including paralytic ileus), concomitant use with full mu-opioid agonists (risk of precipitated withdrawal).
Hypersensitivity to buprenorphine or any component of the formulation,Significant respiratory depression in non-opioid-tolerant patients,Acute or severe bronchial asthma,Known or suspected gastrointestinal obstruction (including paralytic ileus),Monoamine oxidase inhibitor (MAOI) use within past 14 days (relative contraindication; may precipitate serotonin syndrome),Mild to moderate hepatic impairment: use with caution; severe hepatic impairment: contraindicated
No significant food interactions. Grapefruit juice may increase buprenorphine levels via CYP3A4 inhibition; concurrent use is not recommended. Avoid excessive alcohol consumption.
No specific food interactions. Grapefruit juice may increase buprenorphine levels via CYP3A4 inhibition. Avoid excessive alcohol. Maintain a balanced diet to support overall health during treatment.
FDA Pregnancy Category C. First trimester: No increased risk of major malformations based on human data, but animal studies show increased fetal loss and skeletal abnormalities at high doses. Second and third trimesters: Chronic use may lead to neonatal abstinence syndrome (NAS) requiring monitoring. Use only if benefit outweighs risk.
FDA Pregnancy Category C. First trimester: No clear evidence of major malformations in human studies, but animal studies show increased risk of neural tube defects and skeletal anomalies at high doses. Second and third trimesters: Risk of neonatal opioid withdrawal syndrome (NOWS) with chronic use; may cause fetal respiratory depression if used near term.
Buprenorphine is excreted in breast milk with a relative infant dose of 1-2% of maternal weight-adjusted dose. M/P ratio approximately 1.0 based on limited data. The American Academy of Pediatrics considers it compatible with breastfeeding. Monitor infant for sedation, feeding difficulties, and withdrawal if breastfeeding is abruptly stopped.
Buprenorphine is excreted into breast milk with a milk-to-plasma ratio of approximately 0.6 to 1.2. It is generally considered compatible with breastfeeding, but infants should be monitored for sedation and respiratory depression, especially in high maternal doses or with concomitant CNS depressants.
No routine dose adjustment required in pregnancy due to minimal pharmacokinetic changes. However, increased clearance in third trimester may necessitate dose increase (typically 2-4 mg/day) to maintain therapeutic effect. Taper to avoid withdrawal prior to delivery is not recommended due to risk of preterm labor and fetal distress.
No routine dose adjustment is recommended, but dose may need to be increased due to increased clearance and volume of distribution in pregnancy, particularly in the third trimester. Monitor for withdrawal symptoms (e.g., craving, anxiety, abdominal cramping) and consider incremental dose increases (by 2-4 mg) if needed. Postpartum, dose should be titrated back to prepregnancy level over 1-2 weeks.
Buprenorphine is a partial mu-opioid agonist; its ceiling effect reduces respiratory depression risk but may precipitate withdrawal in opioid-dependent patients if administered too soon after full agonists. Sublingual tablets require adequate dissolution under the tongue for 5-10 minutes; advise patient not to swallow or talk during dissolution. Naloxone is combined to deter intravenous misuse; sublingual bioavailability of naloxone is low, but intravenous injection can precipitate withdrawal. Avoid use in patients with severe hepatic impairment due to extensive first-pass metabolism. Monitor for QT prolongation, especially at high doses or with concomitant QT-prolonging drugs.
Buprenorphine is a partial mu-opioid agonist with a ceiling effect on respiratory depression, making it safer than full agonists in overdose. It has high affinity for mu receptors, which can precipitate withdrawal if given to opioid-dependent patients already on full agonists. Sublingual administration avoids first-pass metabolism. Monitor liver function due to hepatotoxicity risk, especially with injectable forms. Long half-life allows every-other-day dosing in maintenance therapy. Naloxone is added in combination products to deter intravenous abuse.
Take buprenorphine exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not consume alcohol or sedatives (benzodiazepines, other opioids) while taking this medication, as it may cause severe drowsiness, respiratory depression, or coma.,Do not drive or operate machinery until you know how buprenorphine affects you; dizziness or drowsiness may occur.,If you miss a dose, take it as soon as remembered; if close to next dose, skip the missed dose and resume normal schedule. Do not double doses.,Store at room temperature away from moisture and heat; keep out of reach of children.,Do not stop abruptly; abrupt discontinuation may cause withdrawal symptoms. Your doctor will taper your dose gradually.,If you experience signs of allergic reaction (rash, hives, swelling, difficulty breathing) or signs of overdose (slow/shallow breathing, severe drowsiness, pinpoint pupils), seek emergency medical attention.,Inform all healthcare providers that you are taking buprenorphine; carry a medication card or alert bracelet.
Take buprenorphine exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not use alcohol, benzodiazepines, or other sedatives while on buprenorphine as it can cause severe drowsiness, respiratory depression, or coma.,Avoid driving or operating heavy machinery until you know how buprenorphine affects you.,Do not stop abruptly; withdrawal symptoms may occur. Taper under medical supervision.,Store safely out of reach of children; accidental ingestion can be fatal.,Inform your doctor if you have liver disease, breathing problems, or are pregnant.,If you miss a dose, take it as soon as possible; skip if almost time for next dose. Do not double dose.
"Buprenorphine, a partial mu-opioid receptor agonist with ceiling effects on respiratory depression, coadministered with Ketobemidone, a full mu-opioid agonist, may produce additive central nervous system (CNS) depression. This synergistic effect can lead to profound sedation, respiratory depression, coma, and death, especially when doses are escalated or in the presence of other CNS depressants. The interaction is particularly dangerous due to buprenorphine's high affinity for mu receptors potentially displacing Ketobemidone and precipitating withdrawal, while simultaneously contributing to CNS depressant effects."
"Buprenorphine, a partial mu-opioid receptor agonist, and triflupromazine, a phenothiazine antipsychotic with strong central nervous system (CNS) depressant properties, exert additive CNS depression when coadministered. This can lead to excessive sedation, respiratory depression, hypotension, and increased risk of coma or death, particularly in elderly or compromised patients. The interaction reduces psychomotor function and may potentiate other adverse effects such as orthostatic hypotension and extrapyramidal symptoms."
"Buprenorphine, a partial mu-opioid receptor agonist, can inhibit CYP3A4 isoenzymes, thereby reducing the hepatic metabolism of Midostaurin, a multikinase inhibitor primarily metabolized by CYP3A4. This results in elevated plasma concentrations of Midostaurin, increasing the risk of dose-dependent toxicities such as QT prolongation, myelosuppression, and gastrointestinal adverse effects. Clinicians should monitor for signs of Midostaurin toxicity and consider dose adjustments."
"Buprenorphine, a partial mu-opioid receptor agonist with ceiling effects on respiratory depression, coadministered with Ketobemidone, a full mu-opioid agonist, may produce additive central nervous system (CNS) depression. This synergistic effect can lead to profound sedation, respiratory depression, coma, and death, especially when doses are escalated or in the presence of other CNS depressants. The interaction is particularly dangerous due to buprenorphine's high affinity for mu receptors potentially displacing Ketobemidone and precipitating withdrawal, while simultaneously contributing to CNS depressant effects."
"Buprenorphine, a partial mu-opioid receptor agonist, and triflupromazine, a phenothiazine antipsychotic with strong central nervous system (CNS) depressant properties, exert additive CNS depression when coadministered. This can lead to excessive sedation, respiratory depression, hypotension, and increased risk of coma or death, particularly in elderly or compromised patients. The interaction reduces psychomotor function and may potentiate other adverse effects such as orthostatic hypotension and extrapyramidal symptoms."
"Buprenorphine, a partial mu-opioid receptor agonist, can inhibit CYP3A4 isoenzymes, thereby reducing the hepatic metabolism of Midostaurin, a multikinase inhibitor primarily metabolized by CYP3A4. This results in elevated plasma concentrations of Midostaurin, increasing the risk of dose-dependent toxicities such as QT prolongation, myelosuppression, and gastrointestinal adverse effects. Clinicians should monitor for signs of Midostaurin toxicity and consider dose adjustments."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUPRENORPHINE HYDROCHLORIDE vs BUPRENORPHINE, answered by our medical review team.
BUPRENORPHINE HYDROCHLORIDE is a Opioid Partial Agonist that works by Partial agonist at mu-opioid receptors and antagonist at kappa-opioid receptors, producing analgesia and reducing opioid withdrawal symptoms.. BUPRENORPHINE is a Opioid Partial Agonist that works by Partial mu-opioid receptor agonist and weak kappa-opioid receptor antagonist; also exhibits high affinity but low intrinsic activity at mu-opioid receptors, producing analgesia and euphoria with a ceiling effect on respiratory depression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUPRENORPHINE HYDROCHLORIDE and BUPRENORPHINE depend on the specific clinical indication. These are both Opioid Partial Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUPRENORPHINE HYDROCHLORIDE is: Sublingual: 8-16 mg once daily. Transdermal: 5-20 mcg/hour applied every 7 days. Injectable: 0.3 mg IM/IV every 6-8 hours as needed.. The standard adult dose of BUPRENORPHINE is: Sublingual tablet: 2-8 mg every 6-8 hours as needed for pain; for opioid use disorder: 12-16 mg once daily. Transdermal patch: 5-20 mcg/h applied every 7 days. IV/IM: 0.3 mg every 6-8 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining BUPRENORPHINE HYDROCHLORIDE and BUPRENORPHINE. Buprenorphine, a partial mu-opioid receptor agonist with ceiling effects on respiratory depression, coadministered with Ketobemidone, a full mu-opioid agonist, may produce additive central nervous system (CNS) depression. This synergistic effect can lead to profound sedation, respiratory depression, coma, and death, especially when doses are escalated or in the presence of other CNS depressants. The interaction is particularly dangerous due to buprenorphine's high affinity for mu receptors potentially displacing Ketobemidone and precipitating withdrawal, while simultaneously contributing to CNS depressant effects. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. BUPRENORPHINE HYDROCHLORIDE is classified as Category C. FDA Pregnancy Category C. First trimester: No increased risk of major malformations based on human data, but animal studies show increased fetal loss and skeletal abnormalities at . BUPRENORPHINE is classified as Category C. FDA Pregnancy Category C. First trimester: No clear evidence of major malformations in human studies, but animal studies show increased risk of neural tube defects and skeletal ano. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.